Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in The Systolic Blood Pressure Intervention Trial

Kidney International

Volumn 87, Issue 1, 2015, Pages 169-175

  Langefeld, Carl D ^a   Divers, Jasmin ^a   Pajewski, Nicholas M ^a   Hawfield, Amret T ^a   Reboussin, David M ^a   Bild, Diane E ^b   Kaysen, George A ^c   Kimmel, Paul L ^d   Raj, Dominic S ^e   Ricardo, Ana C ^f   Wright, Jackson T ^g   Sedor, John R ^h   Rocco, Michael V ^a   Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Patient Centered Outcomes Research Institute (PCORI)   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

African Americans; albuminuria; APOL1; cardiovascular disease; chronic kidney disease; SPRINT

Indexed keywords

ALBUMIN; CREATININE; APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

ADULT; APOL1 GENE; ARTICLE; CARDIOVASCULAR DISEASE; CAROTID ARTERY REVASCULARIZATION; CAROTID ARTERY SURGERY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; PREVALENCE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; AFRICAN AMERICAN; CHRONIC KIDNEY FAILURE; GENETIC VARIATION; GENETICS; MIDDLE AGED;

AFRICAN AMERICANS; APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; FEMALE; GENETIC VARIATION; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84920128507     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.254     Document Type: Article

References (31)

1. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
2. Tzur S, Rosset S, Shemer R et al. Missense mutations in The APOL1 gene are highly associated with end stage kidney disease risk previously attributed to The MYH9 gene. Hum Genet 2010; 128: 345-350.
3. Kopp JB, Nelson GW, Sampath K et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22: 2129-2137.
4. Larsen CP, Beggs ML, Saeed M et al. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 2013; 24: 722-725.
5. Ashley-Koch AE, Okocha EC, Garrett ME et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011; 155: 386-394.
6. Freedman BI, Langefeld CD, Andringa KK et al. End-stage kidney disease in African Americans with lupus nephritis associates with APOL1. Arthritis Rheumatol 2014; 66: 390-396.
7. Lipkowitz MS, Freedman BI, Langefeld CD et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and The rate of kidney function decline in African Americans. Kidney Int 2013; 83: 114-120.
8. Parsa A, Kao WH, Xie D et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196.
9. Fine DM, Wasser WG, Estrella MM et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol 2012; 23: 343-350.
10. Divers J, Nunez M, High KP et al. JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int 2013; 84: 1207-1213.
11. Divers J, Palmer ND, Lu L et al. Gene-gene interactions in APOL1-associated nephropathy. Nephrol Dial Transplant 2014; 29: 587-594.
12. Estrella MM, Wyatt CM, Pearce CL et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int 2013; 84: 834-840.
13. Friedman DJ, Kozlitina J, Genovese G et al. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011; 22: 2098-2105.
14. Freedman BI, Langefeld CD, Turner J et al. Association of APOL1 variants with mild kidney disease in The first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int 2012; 82: 805-811.
15. Foster MC, Coresh J, Fornage M et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 2013; 24: 1484-1491.
16. Ito K, Bick AG, Flannick J et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 2014; 114: 845-850.
17. Appel LJ, Wright JT Jr, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929.
18. Gassman JJ, Greene T, Wright JT Jr. et al. Design and statistical aspects of The African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 2003; 14: S154-S165.
19. The Systolic Blood Pressure Intervention Trial (SPRINT) Steering Committee. The design and rationale of a multi-center clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial. Clin Trials 2014; pii: 1740774514537404 (e-pub ahead of print).
20. Hochberg YA. A sharper Bonferroni for multiple tests of significance. Biometrika 1988; 75: 800-803.
21. Friedman DJ, Pollak MR. Genetics of kidney failure and The evolving story of APOL1. J Clin Invest 2011; 121: 3367-3374.
22. Freedman BI, Langefeld CD. The new era of APOL1-associated glomerulosclerosis. Nephrol Dial Transplant 2012; 27: 1288-1291.
23. Skorecki KL, Wasser WG. Hypertension-misattributed kidney disease in African Americans. Kidney Int 2013; 83: 6-9.
24. Madhavan SM, O'Toole JF, Konieczkowski M et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011; 22: 2119-2128.
25. Criqui MH, Denenberg JO, Ix JH et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA 2014; 311: 271-278.
26. Graham G, Blaha MJ, Budoff MJ et al. Impact of coronary artery calcification on all-cause mortality in individuals with and without hypertension. Atherosclerosis 2012; 225: 432-437.
27. Wright JT Jr., Kusek JW, Toto RD et al. Design and baseline characteristics of participants in The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 17: 3S-16S.
28. Alves TP, Wang X, Wright JT Jr. et al. Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J Am Soc Nephrol 2010; 21: 1361-1369.
29. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
30. Tang H, Peng J, Wang P et al. Estimation of individual admixture: analytical and study design considerations. Genet Epidemiol 2005; 28: 289-301.
31. Gauderman WJ, Morrison JM. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. http://hydra.usc.edu/gxe 2006.